[
  {
    "ts": null,
    "headline": "Globus Medical Stock: Re-Rated After A Solid Year",
    "summary": "Globus Medical saw strong growth from the NuVasive deal. Read why GMED stockâs $81 valuation suggests the easy gains may be over for now.",
    "url": "https://finnhub.io/api/news?id=4a1fedff1088ec0b8e16ab42575de36bf7804b587b19d07bc0c94150afe8daca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731949707,
      "headline": "Globus Medical Stock: Re-Rated After A Solid Year",
      "id": 131460687,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1860536835/image_1860536835.jpg?io=getty-c-w1536",
      "related": "SYK",
      "source": "SeekingAlpha",
      "summary": "Globus Medical saw strong growth from the NuVasive deal. Read why GMED stockâs $81 valuation suggests the easy gains may be over for now.",
      "url": "https://finnhub.io/api/news?id=4a1fedff1088ec0b8e16ab42575de36bf7804b587b19d07bc0c94150afe8daca"
    }
  },
  {
    "ts": null,
    "headline": "Stryker Corp. stock underperforms Monday when compared to competitors",
    "summary": "Stryker Corp. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=9f138529c2b8e8108a34cffece385ba0c0fb0a8d40c0acf3184aae5daf94b328",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731947940,
      "headline": "Stryker Corp. stock underperforms Monday when compared to competitors",
      "id": 131475491,
      "image": "",
      "related": "SYK",
      "source": "MarketWatch",
      "summary": "Stryker Corp. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=9f138529c2b8e8108a34cffece385ba0c0fb0a8d40c0acf3184aae5daf94b328"
    }
  }
]